These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37205634)

  • 1. Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway.
    Ludwig MP; Galbraith MD; Eduthan NP; Hill AA; Clay MR; Tellez CM; Wilky BA; Elias A; Espinosa JM; Sullivan KD
    Cancer Res; 2023 Aug; 83(15):2543-2556. PubMed ID: 37205634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
    Müller CR; Paulsen EB; Noordhuis P; Pedeutour F; Saeter G; Myklebost O
    Int J Cancer; 2007 Jul; 121(1):199-205. PubMed ID: 17354236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma.
    Cissé MY; Pyrdziak S; Firmin N; Gayte L; Heuillet M; Bellvert F; Fuentes M; Delpech H; Riscal R; Arena G; Chibon F; Le Gellec S; Maran-Gonzalez A; Chateau MC; Theillet C; Carrere S; Portais JC; Le Cam L; Linares LK
    Sci Transl Med; 2020 Jun; 12(547):. PubMed ID: 32522803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
    Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
    Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implication of Nrf2 and ATF4 in differential induction of CHOP by proteasome inhibition in thyroid cancer cells.
    Zong ZH; Du ZX; Li N; Li C; Zhang Q; Liu BQ; Guan Y; Wang HQ
    Biochim Biophys Acta; 2012 Aug; 1823(8):1395-404. PubMed ID: 22691366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
    Ooi MG; Hayden PJ; Kotoula V; McMillin DW; Charalambous E; Daskalaki E; Raje NS; Munshi NC; Chauhan D; Hideshima T; Buon L; Clynes M; O'Gorman P; Richardson PG; Mitsiades CS; Anderson KC; Mitsiades N
    Clin Cancer Res; 2009 Dec; 15(23):7153-60. PubMed ID: 19934289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
    Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
    Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification.
    Cornillie J; Wozniak A; Li H; Gebreyohannes YK; Wellens J; Hompes D; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Transl Oncol; 2020 Apr; 22(4):546-554. PubMed ID: 31201607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.
    Bozzi F; Conca E; Laurini E; Posocco P; Lo Sardo A; Jocollè G; Sanfilippo R; Gronchi A; Perrone F; Tamborini E; Pelosi G; Pierotti MA; Maestro R; Pricl S; Pilotti S
    Lab Invest; 2013 Nov; 93(11):1232-40. PubMed ID: 24018792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters.
    Henningsen KM; Manzini V; Magerhans A; Gerber S; Dobbelstein M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
    Yang P; Chen W; Li X; Eilers G; He Q; Liu L; Wu Y; Wu Y; Yu W; Fletcher JA; Ou WB
    Oncotarget; 2016 May; 7(22):32652-63. PubMed ID: 27129163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhythmic control of the ARF-MDM2 pathway by ATF4 underlies circadian accumulation of p53 in malignant cells.
    Horiguchi M; Koyanagi S; Hamdan AM; Kakimoto K; Matsunaga N; Yamashita C; Ohdo S
    Cancer Res; 2013 Apr; 73(8):2639-49. PubMed ID: 23580573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis.
    Lee DM; Kim IY; Seo MJ; Kwon MR; Choi KS
    Exp Mol Med; 2017 Aug; 49(8):e365. PubMed ID: 28798402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 promotes AKT and SP1-dependent metabolism through the pentose phosphate pathway that inhibits apoptosis in response to Nutlin-3a.
    Duan L; Perez RE; Chen L; Blatter LA; Maki CG
    J Mol Cell Biol; 2018 Aug; 10(4):331-340. PubMed ID: 29190376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.